Equanimity AI

Company Overview

Snapshot

Founded in July 2022 by Erez Levanon and Samuel Hazak, Equanimity AI operates with 1-10 employees. The company is currently engaged in clinical pilots for its AI-driven chronic pain assessment platform.

Business overview

Equanimity AI is a digital health startup focused on transforming chronic pain management through artificial intelligence and wearable technology. The company's core technology integrates data from wearables, smartphones, and patient-reported outcomes to create an objective pain map and an Equanimity Pain Score, providing clinicians with quantifiable measures of pain intensity. This platform supports personalized treatment plans and real-time monitoring, aiming to reduce bias in pain reporting. Equanimity AI targets interventional pain clinics and healthcare providers with a B2B SaaS model, with potential expansion into B2B2C, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Patient Remote Monitoring.

Company Intelligence Q&A

What is Equanimity AI's primary focus?

Equanimity AI is dedicated to transforming chronic pain management through an AI-driven platform that provides personalized assessment using artificial intelligence and wearable technology.

Who are the founders of Equanimity AI?

Equanimity AI was co-founded by Erez Levanon, who serves as CEO, and Samuel Hazak, the CTO.

What technology does Equanimity AI utilize?

Equanimity AI leverages continuous passive data collection, multimodal analysis, and AI-driven insights from wearables, smartphones, and patient-reported outcomes to create an objective pain map and score.

Which markets does Equanimity AI target?

Equanimity AI primarily targets interventional pain clinics and healthcare providers with a B2B SaaS model, with potential future expansion into the B2B2C market for patient subscription features.

What is the current stage of Equanimity AI's product development?

Equanimity AI's product is currently in the Beta stage, with clinical pilots underway to validate its chronic pain evaluation and management solution.